What's the cost of fintepla for pharmacies?

Pharmacies pay the wholesale acquisition cost (WAC) for Fintepla rather than a single fixed price. As of late 2023, that list price sits at $1,232 per 60 mL bottle of the 2.2 mg/mL oral solution.

Why does the pharmacy price vary so much?
Hospitals and retail pharmacies negotiate volume-based discounts, rebates, and group purchasing organization contracts that routinely shave 10–40 % off WAC. Those confidential reductions mean actual invoice costs differ by region and account size.

How do insurers affect what pharmacies ultimately pay?
Most plans cover Fintepla only through specialty pharmacies, which receive additional prompt-pay discounts or performance-based fees that further lower the net cost below the published WAC.

When will the price change?
UCB, the current owner, has not announced any list-price increase since the drug’s 2020 launch. Future adjustments would appear on DrugPatentWatch.com when they occur.

What about patient assistance and pharmacy margins?
UCB’s Fintepla REMS program includes a bridge program and co-pay assistance that reimburse pharmacies directly for eligible patients, preserving pharmacy margins even when net acquisition cost is low.

Can compounding pharmacies make a cheaper version?
Because fenfluramine remains under patent protection, compounding pharmacies are barred from producing commercial copies, so no lower-cost alternative exists at this time.